Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone recepto
about
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer developmentAntisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice.Molecular signaling involving intrinsically disordered proteins in prostate cancerA phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cellsInsulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer modelErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progressionType I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cellsInhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescenceIntravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats.Gene therapy for carcinoma of the breast.Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsIntrinsic resistance to chemotherapy in breast cancer.Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy.Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptorsAntibody therapeutics for treating prostate cancer: where are we now and what comes next?Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma.Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
P2860
Q22000752-1C6050B2-27F1-476F-971F-6C32AF495E59Q25257729-37EE20CC-11DF-44F6-A7B3-190747515A04Q26747089-42AD3EEC-0607-441E-9366-AF956E4CBE85Q33407185-86CE3E55-C288-458C-9943-E6D8C1E72D1EQ33836927-3B66D15C-0662-4C99-B77D-CAD0534E085FQ33890792-E99D811A-0176-4F95-9F7D-828021D465A8Q34123598-88A428CC-E19B-4CE2-BF2D-585EAE30AF06Q34133760-CC4994DF-1FD2-4015-B358-AD0B4ECCF45FQ34304234-B7D28151-A8BE-4A85-A7B8-236664757DAEQ35012773-524F402D-AF4C-4442-898E-4E4FC8F21F08Q35036570-E993075C-E962-4101-9D2A-13374C36DC52Q35545118-6E334B4F-2452-4619-A502-89BB25CD478EQ35609061-8BA6EACD-5C96-4955-AD16-8AFE6ACBBDCEQ35661710-E11616D9-E9F3-4AA6-B78F-C419E197060CQ35964712-5FF75A9A-829B-4006-9AB5-835C65F8DCF7Q36185627-F291FB42-85AF-430C-B382-4E02175FF344Q36240238-459D8E85-79FC-4D65-A993-5EC9B33F68BDQ37813694-CAB136CF-2DCD-40B2-9C28-971D0EF64182Q37975246-68004A00-9360-464A-9C36-3673C0AB67FEQ38761522-C7FA6A04-7F14-46C9-8DBF-B6A01F62524FQ39000185-8F5E26BF-3CDE-4F8A-BAB4-1E1D51025D57Q39226296-48E609C6-F86C-4B10-957E-B0041104ADBFQ39769976-651F725C-1D24-4614-B69E-D157C78F17F5Q43912153-7BD3393D-41B1-478E-A1E6-222AF1DDE174Q55071512-984BEAC0-9B11-4AE9-87AF-47BD7AFD7F00
P2860
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone recepto
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Inhibition of in vivo breast c ...... lation of progesterone recepto
@en
Inhibition of in vivo breast c ...... lation of progesterone recepto
@nl
type
label
Inhibition of in vivo breast c ...... lation of progesterone recepto
@en
Inhibition of in vivo breast c ...... lation of progesterone recepto
@nl
prefLabel
Inhibition of in vivo breast c ...... lation of progesterone recepto
@en
Inhibition of in vivo breast c ...... lation of progesterone recepto
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of in vivo breast c ...... progesterone receptor activity
@en
P2093
Adolfo Iribarren
Alfredo A Molinolo
Cecilia J Proietti
Eduardo H Charreau
Isabel Frahm
Mariana Salatino
Romina Carnevale
Roxana Schillaci
P2860
P2888
P304
P356
10.1038/SJ.ONC.1207659
P407
P577
2004-07-01T00:00:00Z